Skye Bioscience, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Punit Dhillon (CEO) and John P. Sharp (CFO) each signed standard Sarbanes-Oxley Section 302 and 906 certifications for the Q2 2026 10-Q (quarter ended June 30, 2026), filed August 14, 2026. The certifications attest that the report contains no material misstatements, financial statements fairly present the company's condition and results, and disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine SOX compliance certification exhibits; boilerplate attestation with no operational substance, transaction, or disclosure change.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.